v3.26.3
Business Combination - Narrative (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 14, 2026
USD ($)
Sep. 30, 2026
USD ($)
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Business Combination [Line Items]              
Acquisition-related contingent consideration, net of current portion   $ 23,979,000 $ 23,979,000   $ 23,979,000   $ 1,589,000
Intangible asset amortization - operating expenses     3,700,000 $ 3,300,000 10,100,000 $ 9,800,000  
Goodwill acquired         $ 88,421,000    
Convergent Genomics, Inc.              
Business Combination [Line Items]              
Equity interest acquired 100.00%            
Acquisition consideration $ 178,200,000            
Acquisition consideration 154,700,000            
Cash acquired from acquisition 6,800,000            
Maximum contingent consideration to be paid 30,000,000.0            
Acquisition-related contingent consideration, net of current portion $ 23,500,000            
Business combination, consideration transferred, escrow deposits release period 12 months            
Acquisition-related cost, expense     1,700,000        
Acquisition date   0          
Operating loss   $ 300,000          
Intangible asset amortization - operating expenses     $ 200,000        
Convergent Genomics, Inc. | Developed technology | Discount rate              
Business Combination [Line Items]              
Measurement input             0.15
Convergent Genomics, Inc. | Cash Retention              
Business Combination [Line Items]              
Retention arrangements $ 1,600,000            
Convergent Genomics, Inc. | Restricted Stock Units              
Business Combination [Line Items]              
Retention arrangements 2,700,000            
Convergent Genomics, Inc. | Fair Value of Milestone Payments              
Business Combination [Line Items]              
Acquisition-related contingent consideration, net of current portion 23,500,000            
Convergent Genomics, Inc. | Settlement of Vested Stock Options              
Business Combination [Line Items]              
Acquisition consideration 13,100,000            
Convergent Genomics, Inc. | Amounts Placed in Escrow              
Business Combination [Line Items]              
Acquisition consideration 16,000,000.0            
Convergent Genomics, Inc. | Amounts Placed in Escrow | Post-Closing Adjustments              
Business Combination [Line Items]              
Acquisition consideration 1,000,000.0            
Convergent Genomics, Inc. | Amounts Placed in Escrow | Indemnification Obligations              
Business Combination [Line Items]              
Acquisition consideration 15,000,000.0            
Convergent Genomics, Inc. | Deposits for Post-closing Matters              
Business Combination [Line Items]              
Acquisition consideration 200,000            
Convergent Genomics, Inc. | Seller Transaction Costs              
Business Combination [Line Items]              
Acquisition consideration $ 1,400,000